- Conditions
- Nonvalvular Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Baim Institute for Clinical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 817 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Anchorage, Alaska • Orange, California • Clearwater, Florida + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 66
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Nonvalvular Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78,517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Multiple Locations, Washington
- Conditions
- Non-Valvular Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Atrial Fibrillation
- Interventions
- Biosense Webster irrigated tip catheter, Pulmonary vein isolation, ICE catheter placed through one of two existing 8F sheaths
- Device · Procedure
- Lead sponsor
- Gregory Jones
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Kingsport, Tennessee
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- warfarin, apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 20,976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 284
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban, Warfarin, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
- Conditions
- Atrial Fibrillation
- Interventions
- Feedback
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Nonvalvular Atrial Fibrillation, Severe Degenerative Mitral Regurgitation
- Interventions
- MitraClip TMVR and Watchman LAAO
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
- Interventions
- LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Device · Drug
- Lead sponsor
- Brian O'Neill MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Persistent Nonvalvular Atrial Fibrillation
- Interventions
- Certoparin
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey